Certain rare genetic variants tied to Parkinson’s and other diseases raise the risk of developing ALS by more than three times, per a study.

Fourteen years into an ALS diagnosis, columnist Dagmar Munn decides in a visit to the dermatologist that she's earned her little skin bumps.

Ractigen's therapy candidate RAG-17 was safe across all tested doses and showed early signs of effectiveness in SOD1-ALS ...

The Phase 1 clinical trial is expected to enroll about 60 participants to test how safe and well tolerated multiple doses of ...

NRG Therapeutics will use a new grant to advance preclinical studies of its class of oral small molecules as a potential ...

Columnist Kristin Neva reflects on her last state park outing with her husband, which seems a lifetime ago to her now.

The U.S. Food and Drug Administration (FDA) has given the green light to Dr.Noah Biotech to initiate a Phase 1 clinical trial of NDC-011, a combination therapy for amyotrophic lateral sclerosis (ALS), ...

AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the ...